Clinical trials: sponsored by Anhui Provincial Hospital
Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer
Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy
This is a single-center, single-arm, open-label, Phase 2 clinical trial (the SCOPE study) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (SKB264) combined with toripalimab as a second-line…
- Conditions
- Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile Cancer
- Trial name
- SCOPE (NCT07907861)
- Testing
- Sacituzumab Tirumotecan (SKB264), Toripalimab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Anhui Provincial Hospital
Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody)
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
This is a randomized, controlled, multicenter clinical study to evaluate AK104 in FIGO 2018 stage III-IV ovarian cancer subjects who were assessed to be at high perioperative risk and/or unable to achieve R0 resection prior to…
- Conditions
- Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy
- Trial name
- NCT06542549
- Testing
- AK104
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Provincial Hospital
Non-small Cell Lung Cancer, Radiotherapy Side Effect
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer.
- Trial name
- NCT05269485
- Testing
- High-dose hypofractionated radiotherapy, Low-dose hypofractionated radiotherapy
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Aplastic Anaemia
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of Aplastic Anemia (AA)
- Trial name
- NCT07885982
- Testing
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Anhui Provincial Hospital
Biliary Tract Cancer
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
This is a prospective, multicenter, single-arm, phase II clinical study designed to explore the efficacy and safety of zanidatamab in combination with liposomal irinotecan and capecitabine as second-line therapy for HER2-positive…
- Trial name
- ZENITH (NCT07841873)
- Testing
- Zanidatamab
- Volunteers
- 15 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer.
- Trial name
- ZINC-1LT/IOHCC (NCT07793695)
- Testing
- Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Colorectal Liver Metastases, Colorectal Neoplasms
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline…
- Conditions
- Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms
- Trial name
- NCT07830576
- Testing
- Multimodal Predictive Evaluation
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Anhui Provincial Hospital
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
External Transportability Validation, Implementation Readiness, and Outcome Association of the TransHepMet-Mort Liver Metabolic Mortality Risk Model
Study data were derived from existing electronic health records at our hospital's health examination center between January 1, 2018, and December 31, 2024.
- Trial name
- THM-ImpReadine (NCT07816211)
- Where
- China
- Volunteers
- 269,901 people
- Sponsor
- Anhui Provincial Hospital
Locally Advanced Cervical Cancer
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
This prospective, single-center, single-arm, phase II study will evaluate perioperative adebrelimab in patients with locally advanced cervical cancer.
- Trial name
- ADE-LACC (NCT07811375)
- Testing
- Adebrelimab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC)
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy.
- Trial name
- NCT07782632
- Testing
- Baseline Liver Volume Volumetric Analysis
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell…
- Trial name
- NCT06294691
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Cancer Treatment-induced Thrombocytopenia (CTIT)
Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia
Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia
- Trial name
- NCT06898983
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Anhui Provincial Hospital
Abnormal Fetal Head Position
Trial of Ultrasound-guided Rotation for Normalizing Head Position
Intrapartum Ultrasound-Guided Early Manual Rotation for Correcting Abnormal Fetal Head Position The goal of this clinical trial is to learn whether using ultrasound during labor, followed by early manual rotation of the baby's…
- Trial name
- TURN-HEAD Tria (NCT07781189)
- Testing
- Trial of Ultrasound-guided Rotation for Normalizing Head position
- Volunteers
- 164 people
- Sponsor
- Anhui Provincial Hospital
Cervical Cancer, HPV DNA
Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer
This prospective observational study will evaluate whether changes in circulating tumor human papillomavirus DNA (ctHPV-DNA) after radical surgery can help predict the risk of recurrence in patients with HPV-associated cervical…
- Trial name
- NCT07782697
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Anhui Provincial Hospital
Hematologic Disease and Disorders
Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.
- Trial name
- NCT07782684
- Testing
- Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Provincial Hospital
Non-Small Cell Lung Cancer
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has been demonstrated to be able to increase the survival of patients with metastatic driven-genes negative non-small cell lung cancer.
- Trial name
- NCT05348668
- Testing
- Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
Targeted Biopsy, Rapid Pathology, and Immediate Surgery in USTC High-Risk Prostate Cancer: A Prospective Multicenter Study
This multicenter, prospective, single-arm study evaluates a novel streamlined pathway for men at high risk of clinically significant prostate cancer (csPCa) identified by the USTC model (probability ≥0.60).
- Trial name
- NCT07709338
- Testing
- Targeted Biopsy, Intraoperative Rapid Pathology, and Immediate Radical Prostatectomy (FROST-RP)
- Volunteers
- 150 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC)
HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC).
- Trial name
- HCC-MPDS (NCT07700082)
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Anhui Provincial Hospital
Thrombocytopenia, Hematologic Malignacies
Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation
This is a single-arm, early safety and feasibility exploratory study to evaluate the efficacy and safety of MegaLT Injection in promoting platelet recovery after umbilical cord blood transplantation.
- Conditions
- Thrombocytopenia, Hematologic Malignacies, Platelet Recovery After Umbilical Cord Blood Transplantation
- Trial name
- NCT07696767
- Testing
- MegaLT Injection
- Volunteers
- 7 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent.
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Adjuvant Therapy, Machine Learning
- Trial name
- HCC (NCT07562763)
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- Anhui Provincial Hospital